Zydus signs deal to market Neovii's Grafalon in India

India’s Zydus group has entered into an in-licensing agreement with independent Swiss biopharma company Neovii to launch Grafalon (anti T-lymphocyte immunoglobulin), an immunosuppressant extensively used in solid organ transplants and stem cell transplant, in India. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine. With the inclusion of ‎Grafalon, Zydus Trans-immune becomes a leading player in transplant-immuno therapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant. Financial terms of the accord were not disclosed.

Grafalon (formerly commercialized as ATG Fresenius) is used as a part of immunosuppressive regimens (induction protocol) for the prevention and treatment of rejection in solid organ transplantation, prevention of graft versus host disease in stem cell transplantation.